Back to Journals » Drug Design, Development and Therapy » Volume 13

A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers

Total article views   Abstract views HTML views PDF downloads Totals
6,021 Dovepress* 4,251 1,095+ 1,024 5,346
PubMed Central* 0 675 174 675
Totals 4,251 1,770 1,198 6,021
*Since 29 March 2019
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
2 0 0 0 1 1

View citations on PubMed Central and Google Scholar